Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia. Issue 11 (19th September 2022) - Daver, Naval; Jonas, Brian A.; Medeiros, Bruno C.; Patil, Upen; Yan, Mark